3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
6
NETWORK
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Radiotherapy
213
Cisplatin
180
Cyclophosphamide
168
Doxorubicin
135
Paclitaxel
125
Vincristine
124
Filgrastim
121
Etoposide
103
Carboplatin
100
Methotrexate
83
Gemcitabine
82
Docetaxel
78
Cytarabine
78
Gene Expression Profiling
74
Fluorouracil
74
Prednisone
71
Granulocyte Colony-Stimulating Factor
66
Dexamethasone
66
Leucovorin
62
Polymerase Chain Reaction
47
Immunohistochemistry
46
Microarray Analysis
40
Daunorubicin
38
Irinotecan
37
Ifosfamide
37
Temozolomide
35
Cetuximab
33
Amplified Fragment Length Polymorphism Analysis
33
Peripheral Blood Stem Cell Transplantation
32
Mercaptopurine
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
NETWORK
×
belantamab mafodotin
×
Clear all
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled
NCT03732703
2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2
Completed
103 enrolled